BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Market News

Caterpillar’s revenue surges 24% to $20.5 billion as volume and pricing both accelerate, lifting margins to 20.9%

Moe Alsumidaie, MBA, MSF by Moe Alsumidaie, MBA, MSF
August 18, 2026
in Market News
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

Caterpillar reported second-quarter 2026 sales and revenues of $20.5 billion, a 24% increase from $16.6 billion in the same quarter last year, driven by $3.1 billion in higher sales volume and $595 million in favorable price realization. Operating profit margin expanded to 20.9% from 17.3% year-over-year, while adjusted operating margin reached 21.9% from 17.6%. The company generated its first-ever single-quarter revenue exceeding $20 billion, signaling sustained demand across all three primary segments.

The $3.974 billion revenue increase breaks down to $3.1 billion from higher sales volume, primarily equipment sales to end users, and $595 million from price realization. Construction Industries led segment growth at 35%, followed by Resource Industries at 20% and Power & Energy at 17%. Geographically, North America accelerated fastest at 37% growth, while Asia/Pacific grew only 4%. Profit per share reached $7.77 compared with $4.62 in the prior year quarter; adjusted profit per share was $8.17 versus $4.72. The company deployed $2.2 billion in the quarter for share repurchases ($1.5 billion) and dividends ($0.7 billion), while operating cash flow totaled $4.4 billion and enterprise cash stood at $6.7 billion. The document provides no forward guidance for future quarters or full-year 2026 results.

What it means

The 24% revenue growth substantially outpaces Caterpillar’s full-year 2025 growth rate of 4.3%, indicating a material acceleration in underlying demand rather than a seasonal or one-time event. The composition of the gain matters: volume growth of $3.1 billion reflects genuine end-user equipment purchases, not inventory building or channel stuffing, while $595 million in price realization shows the company is capturing pricing power without demand destruction. The fact that all three segments grew and all four geographic regions expanded (North America most sharply) suggests the strength is broad-based rather than concentrated in a single market or product line.

Year-by-year revenue growth shows Q2 2026 as a sharp break from Caterpillar’s recent trend, with volume and pricing both contributing to the jump. Interactive: hover for values. Official data via SEC EDGAR.

Operating margin expansion to 20.9% from 17.3% year-over-year, and adjusted margin to 21.9% from 17.6%, indicates that volume and pricing gains are flowing through to profit at a rate faster than revenue growth alone would predict. This suggests either favorable product mix (higher-margin equipment), manufacturing leverage as fixed costs spread across higher output, or both. The 16.5% operating margin reported for full-year 2025 sits well below the 20.9% achieved in this quarter, raising the question of whether Q2 2026 represents a cyclical peak or a sustained step up in profitability.

BullScope TerminalYou just read CATERPILLAR INC’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

The open question the document leaves unresolved is whether this momentum persists or represents a pull-forward of demand. The company cites “strong order rates and a growing backlog” but provides no quantified backlog figures, forward guidance, or commentary on demand visibility beyond the current quarter. The absence of any forward statement, no raised, cut, or affirmed guidance, means the market has no official signal from management about whether the company expects this growth rate to continue, decelerate, or accelerate in the second half of 2026.

What to watch

The next material disclosure will be Caterpillar’s third-quarter 2026 earnings release, expected in late October or early November 2026, which will reveal whether the 24% revenue growth and 20.9% operating margin represent a sustained new operating level or a cyclical peak. Interim signals will come from any investor conference calls, machinery order data, or backlog commentary the company provides in earnings calls or investor presentations before then.

Source: the company’s 8-K filed 2026-08-04 with the SEC.

BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read CATERPILLAR INC’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie, MBA, MSF

Moe Alsumidaie, MBA, MSF

Moe Alsumidaie, MBA, MSF is the Chief Editor of BullScope. Trained in finance, with a Master of Science in Finance and an MBA, he spent years inside large public healthcare companies including Abbott, Genentech, and Roche, learning how the businesses behind the filings actually run. As a journalist and Chief Editor of The Clinical Trial Vanguard, his reporting has appeared in Applied Clinical Trials, The American Journal of Managed Care, and CNET, and has been cited in U.S. Supreme Court proceedings. At BullScope he brings those disciplines together: every note starts in the SEC filings, runs through published methodology, and shows its work.

Recommended For You

Adobe names Chakravarthy CEO as Narayen steps to executive chair

by Moe Alsumidaie, MBA, MSF
September 9, 2026
0

Adobe's board has named Anil Chakravarthy president and chief executive officer effective December 1, 2026, replacing Shantanu Narayen, who

Read moreDetails

AbbVie Reaffirms 2026 Guidance After Closing $10.9 Billion Apogee Acquisition

by Moe Alsumidaie, MBA, MSF
September 4, 2026
0

AbbVie completed its acquisition of Apogee Therapeutics for $10.9 billion in cash, adding two late-stage immunology assets to its pipeline

Read moreDetails

Moderna raises $2.6 billion in zero-coupon convertibles as revenue collapses, betting oncology turnaround

by Moe Alsumidaie, MBA, MSF
September 3, 2026
0

Moderna priced a $2.6 billion offering of convertible senior notes due 2032 on August 28, 2026, upsized from an initially planned $2.0 bill

Read moreDetails

Caterpillar renews three-year credit facility with unchanged $4 billion commitment as borrowing costs shift to SOFR

by Moe Alsumidaie, MBA, MSF
September 2, 2026
0

Caterpillar Inc. has executed a fifth amendment to its revolving credit agreement, dated August 27, 2026, maintaining a three-year facility

Read moreDetails

Boeing renews 364-day credit line as operating margin stays thin at 4.8%

by Moe Alsumidaie, MBA, MSF
September 1, 2026
0

Boeing has executed a new 364-day revolving credit agreement dated August 24, 2026, replacing its prior facility from August 25, 2025. The

Read moreDetails
Next Post

Hill or Cliff? The One Exchange That Defines Merck Right Now

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

UPS: The Margin Story the Filings Tell vs. the One the Market Is Buying

August 12, 2026

One drug carries the revenue. The next one just got complicated.

September 2, 2026

Disney’s Numbers Say One Thing. The Stock Price Says Another.

August 11, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.